Vetvicka V, Vashishta A, Saraswat-Ohri S, Vetvickova J. Procathepsin D and cancer: From molecular biology to clinical applications. World J Clin Oncol 2010; 1(1): 35-40
Corresponding Author of This Article
Vaclav Vetvicka, PhD, Professor, Department of Pathology, University of Louisville, 511 S. Floyd, Louisville, KY 40202, United States. email@example.com
Article-Type of This Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Procathepsin D and cancer: From molecular biology to clinical applications
Vaclav Vetvicka, Aruna Vashishta, Sujata Saraswat-Ohri, Jana Vetvickova
Vaclav Vetvicka, Jana Vetvickova, Department of Pathology, University of Louisville, Louisville, KY 40202, United States
Aruna Vashishta, Sujata Saraswat-Ohri, Kentucky Spinal Cord Injury Centre, Department of Neurological Surgery, University of Louisville, Louisville, KY 40202, United States
Author contributions: All authors contributed equally to this work.
Correspondence to: Vaclav Vetvicka, PhD, Professor, Department of Pathology, University of Louisville, 511 S. Floyd, Louisville, KY 40202, United States. firstname.lastname@example.org
Telephone: +1-502-8521612 Fax: +1-502-8521177
Received: June 11, 2010 Revised: August 24, 2010 Accepted: September 1, 2010 Published online: November 10, 2010
Procathepsin D (pCD) is overexpressed and secreted by cells of various tumor types including breast and lung carcinomas. pCD affects multiple features of tumor cells including proliferation, invasion, metastases and apoptosis. Several laboratories have previously shown that the mitogenic effect of pCD on cancer cells is mediated via its propeptide part (APpCD). However, the exact mechanism of how pCD affects cancer cells has not been identified. Recent observations have also revealed the possible use of pCD/APpcD as a marker of cancer progression. The purpose of this review is to summarize the three major potentials of pCD-tumor marker, potential drug, and screening agent.